Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL946263 | 0.81 | LMNA (0.49) | LMNAMAPTPOLBPKMNPSR1 | |
| SCHEMBL10757522 | 0.77 | POLB (0.42) | LMNAMAPTPOLBPKMNPSR1 | |
| SCHEMBL11039174 | 0.76 | LMNA (0.44) | LMNAMAPTPOLBPKMNPSR1 | |
| SCHEMBL435089 | 0.76 | LMNA (0.49) | LMNAMAPTPOLBPKMNPSR1 | |
| SCHEMBL11211592 | 0.75 | LMNA (0.46) | LMNAMAPTPOLBPKMNPSR1 | |
| SCHEMBL11109613 | 0.75 | LMNA (0.46) | LMNAMAPTPOLBPKMNPSR1 | |
| SCHEMBL18536181 | 0.74 | ALDH1A1 (0.49) | LMNAMAPTPOLBPKMNPSR1 | |
| SCHEMBL10737745 | 0.74 | PKM (0.50) | LMNAMAPTPOLBPKMNPSR1 | |
| SCHEMBL15485106 | 0.74 | LMNA (0.51) | LMNAMAPTPOLBPKMNPSR1 | |
| SCHEMBL16127631 | 0.74 | LMNA (0.48) | LMNAMAPTPOLBPKMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | CFD, TFPI, CFH | LMNA 2178/4885MAPT 4161/4885POLB 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.